31582 Federal Register / Vol. 72, No.
109 / Thursday, June 7, 2007 / Notices
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than June 22,
2007.
A. Federal Reserve Bank of Atlanta
(David Tatum, Vice President) 1000
Peachtree Street, NE., Atlanta, Georgia
30309:
1. Heys Edward McMath, III,
Savannah, Georgia; to retain voting
shares of First National Corporation,
and thereby indirectly retain voting
shares of First National Bank, both of
Savannah, Georgia.
B. Federal Reserve Bank of St. Louis
(Glenda Wilson, Community Affairs
Officer) 411 Locust Street, St. Louis,
Missouri 63166-2034:
1. Wilson–Gardner Family Control
Group, Jackson, Mississippi, which
consists of Fred Gillaspy Wilson,
individually and as trustee of the
Gardner Trust, Jackson, Mississippi;
Rufus K. Gardner, Winona, Mississippi,
and Joseph E. Gardner, Austin, Texas, as
trustees of the Gardner Trust; Alice King
Harrison, Forrest City, Arkansas; John
Frederick Wilson, Jackson, Mississippi;
Margaret Gardner Wilson, Ridgeland,
Mississippi; Margaret Wilson Ethridge,
Madison, Mississippi; Ermis King
Wilson, Sterlington, Louisiana; Edna
Earl Douglas, Memphis, Tennessee;
Alison Wilson Page, Sterlington,
Louisiana; and Ermis M. Wilson,
Sterlington, Louisiana; to retain control
of Commerce Bancorp, Inc., and thereby
indirectly retain voting shares of Bank
of Commerce, both of Greenwood,
Mississippi.
Board of Governors of the Federal Reserve
System, June 4, 2007.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E7–11009 Filed 6–6–07; 8:45 am]
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR Part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
rwilkins on PROD1PC63 with NOTICES
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
VerDate Aug<31>2005 20:59 Jun 06, 2007 Jkt 211001
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
Web site at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than July 3, 2007.
A. Federal Reserve Bank of
Richmond (A. Linwood Gill, III, Vice
President) 701 East Byrd Street,
Richmond, Virginia 23261-4528:
1. Bank of America Corporation,
Charlotte, North Carolina; to acquire 100
percent of the voting shares of ABN
AMRO North America Holding
Company, Chicago, Illinois, and thereby
indirectly acquire voting shares of
LaSalle Bank Corporation, Chicago,
Illinois; LaSalle Bank Midwest National
Assocation, Troy, Michigan; and LaSalle
Bank National Association, Chicago,
Illinois.
Board of Governors of the Federal Reserve
System, June 1, 2007.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E7–10916 Filed 6–6–07; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Toxicology Program (NTP)
Interagency Center for the Evaluation
of Alternative Toxicological Methods
(NICEATM); Request for Ocular
Irritancy Test Data From Human,
Rabbit, and In Vitro Studies Using
Standardized Testing Methods
AGENCY: National Institute of
Environmental Health Sciences
(NIEHS), National Institutes of Health
(NIH).
ACTION: Request for submission of
relevant data.
PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 E:\FR\FM\07JNN1.SGM
SUMMARY: The Interagency Coordinating
Committee on the Validation of
Alternative Methods (ICCVAM) and
NICEATM are collaborating with the
European Centre for the Validation of
Alternative Methods (ECVAM) to
evaluate the validation status of in vitro
test methods for assessing the ocular
irritation potential of substances. On
behalf of the ICCVAM, NICEATM
requests data on substances tested for
ocular irritancy in humans, rabbits, and/
or in vitro. These data will be used to:
(1) Review the state-of-the-science in
regard to the availability of accurate and
reliable in vitro test methods for
assessing the range of potential ocular
irritation activity, including whether
ocular damage is reversible or not and
(2) expand NICEATM’s high-quality
ocular toxicity database. In vitro test
methods for which data are sought
include, but are not limited to: (1) The
Bovine Corneal Opacity and
Permeability (BCOP) test, (2) the
Isolated Rabbit Eye (IRE) test, (3) the
Isolated Chicken Eye (ICE) test, and (4)
the Hen’s Egg Test—Chorioallantoic
Membrane (HET–CAM).
DATES: Data should be received by July
23, 2007. Data received after this date
will be considered as feasible.
ADDRESSES: Dr. William S. Stokes,
NICEATM Director, NIEHS, P.O. Box
12233, MD EC–17, Research Triangle
Park, NC 27709, (fax) 919–541–0947, (e-
mail) niceatm@niehs.nih.gov. Courier
address: NICEATM, 79 T.W. Alexander
Drive, Building 4401, Room 3128,
Research Triangle Park, NC 27709.
Responses can be submitted
electronically at the ICCVAM–
NICEATM Web site: http://
iccvam.niehs.nih.gov/contact/
FR_pubcomment.htm or by e-mail, mail,
or fax.
FOR FURTHER INFORMATION CONTACT:
Other correspondence should be
directed to Dr. William S. Stokes (919–
541–2384 or niceatm@niehs.nih.gov).
SUPPLEMENTARY INFORMATION:
Background
In October 2003, the U.S.
Environmental Protection Agency (EPA)
submitted to ICCVAM a nomination
with several activities related to
reducing, replacing, and refining the use
of rabbits in the current in vivo eye
irritation test method (Federal Register
Vol. 69, No. 57, pp 13859–13861, March
24, 2004). In response to this
nomination, ICCVAM completed an
evaluation of the validation status of the
BCOP, ICE, IRE, and HET–CAM test
methods for identifying severe
(irreversible) ocular irritants/corrosives
using the United Nations Globally
07JNN1
 Federal Register / Vol. 72, No. 109 / Thursday, June 7, 2007 / Notices
Harmonized System of Classification
and Labeling of Chemicals (GHS), the
EPA, and the European Union hazard
classification systems. NICEATM and
ICCVAM prepared a comprehensive
background review document (BRD) on
each of the four in vitro test methods.
Each BRD included an analysis of test
method performance (i.e., reliability and
relevance) as compared to the in vivo
rabbit eye reference test method, based
on all available data. ICCVAM
developed recommendations on the
usefulness and limitations of these in
vitro test methods for identifying ocular
corrosives/severe irritants after
considering the BRDs, comments
received from the public and the
Scientific Advisory Committee on
Alternative Toxicological Methods
(SACATM), and comments and
recommendations received from an
independent expert panel (Federal
Register Vol. 70, No. 53, pp 13513–
13514, March 21, 2005 and Vol. 70, No.
211, p 66451, November 2, 2005).
ICCVAM is now reviewing the
validation status of these and other in
vitro test methods for identifying
nonsevere ocular irritants (i.e., those
that induce reversible ocular damage)
and non-irritants.
Request for Data
As part of the review process,
NICEATM requests the submission of
data from substances tested for ocular
irritancy in humans, rabbits, and/or in
vitro. Data received by July 23, 2007 will
be compiled and added to the database
maintained by NICEATM and utilized
where appropriate in the evaluation of
in vitro ocular irritation test methods.
Data received after this date will also be
considered and used where applicable
for future evaluation activities. All
information submitted in response to
this notice will be made publicly
available upon request to NICEATM.
When submitting substance and
protocol information/test data, please
reference this Federal Register notice
and provide appropriate contact
information (name, affiliation, mailing
address, phone, fax, e-mail, and
sponsoring organization, as applicable).
NICEATM prefers data to be
submitted as copies of pages from study
notebooks and/or study reports, if
available. Raw data and analyses
available in electronic format may also
be submitted. Each submission for a
substance should preferably include the
following information, as appropriate:
rwilkins on PROD1PC63 with NOTICES
• Common and trade name.
• Chemical Abstracts Service Registry
Number (CASRN).
• Chemical and/or product class.
• Commercial source.
VerDate Aug<31>2005 20:59 Jun 06, 2007 Jkt 211001
• In vitro test protocol used.
• Rabbit eye test protocol used.
• Human eye test protocol used.
• Individual animal/human or in
vitro responses at each observation time
(i.e., raw data).
• The extent to which the study
complied with national/international
Good Laboratory Practice (GLP)
guidelines.
• Date and testing organization.
Additional information on the
submission of data may be obtained at
http://iccvam.niehs.nih.gov/methods/
ocutox/ivocutox.htm.
Background Information on ICCVAM
and NICEATM
ICCVAM is an interagency committee
composed of representatives from 15
federal regulatory and research agencies
that use or generate toxicological
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative methods with regulatory
applicability and promotes the scientific
validation and regulatory acceptance of
toxicological test methods that more
accurately assess the safety and hazards
of chemicals and products and that
refine, reduce, or replace animal use.
The ICCVAM Authorization Act of 2000
(42 U.S.C. 285l–3, available at http://
iccvam.niehs.nih.gov/docs/about_docs/
PL106545.pdf) established ICCVAM as a
permanent interagency committee of the
NIEHS under NICEATM. NICEATM
administers the ICCVAM and provides
scientific and operational support for
ICCVAM-related activities. NICEATM
and ICCVAM work collaboratively to
evaluate new and improved test
methods applicable to the needs of
federal agencies. Additional information
about ICCVAM and NICEATM is
available on the following Web site:
http://iccvam.niehs.nih.gov.
Dated: May 25, 2007.
Samuel H. Wilson,
Deputy Director, National Institute of
Environmental Health Sciences and National
Toxicology Program.
[FR Doc. E7–10966 Filed 6–6–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institution for Occupational
Safety and Health (NIOSH) Advisory
Board on Radiation and Worker Health
(ABRWH or Advisory Board)
Correction: This notice was published
in the Federal Register on May 22,
PO 00000 Frm 00035 Fmt 4703 Sfmt 4703
31583
2007, Volume 72, Number 98, pages
28697–28698. The meeting was
originally scheduled to be held at the
Westin Westminster Hotel. The
Committee will now convene at the
Sheraton Denver West Hotel, 360 Union
Boulevard, Lakewood, Colorado 80228,
Phone 303.987.2000, Fax 303.969.0263.
Times and Dates:
9 a.m.–5 p.m., June 11, 2007.
8 a.m.–3 p.m., June 12, 2007.
Contact Person for More Information:
Dr. Lewis V. Wade, Executive Secretary,
NIOSH, CDC, 4676 Columbia Parkway,
Cincinnati, Ohio 45226, Telephone
513.533.6825, Fax 513.533.6826.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: May 31, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office Centers for Disease Control
and Prevention.
[FR Doc. E7–10987 Filed 6–6–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004D–0466]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Substantiation for
Dietary Supplement Claims Made
Under the Federal Food, Drug, and
Cosmetic Act
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by July 9,
2007.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974. All comments should be
E:\FR\FM\07JNN1.SGM 07JNN1